B3. DATA ANALYSIS OF ARV SCALE-UP THERAPY AT THE RAINBOW CLINIC OF MZUZU CENTRAL HOSPITAL IN NORTHERN MALAWI
1CC MTIKA, 1,2JKL YU, 2SCC CHEN, 1H JUMA,
1Rainbow Clinic, Mzuzu Central Hospital, Mzuzu, Malawi
2Taiwan Medical Mission
Background: Mzuzu Central Hospital (MCH) has started ARV clinic (named as Rainbow Clinic) on July 1st 2004. MCH as the only one central hospital in the northern region of Malawi is one of the earlier units to deliver the ARV drugs to the patients after a full training program has been fulfilled for the staff.
Objectives: To review the patients and the staff profile in Rainbow Clinic during the first quarter and expect our quality assurance in the second quarter.
Methodology: Rainbow Clinic has followed the national standard guideline of ARV therapy as well as the master card and patient registration system. All cases’ data like age, sex, clinical staging, drug adherence, general social function and activities were recorded. We also established a staff performance surveillance system to monitor staff’s clinical service. The data were analyzed with ANOVA and P<0.05 was considered statistically significant.
Results: Since July 1st 2004, Rainbow Clinic has a total number of 625 patients for the first quarter. Among them, 507 cases were new registered cases and 118 were transfer-in cases. Male to female is 309 to 362 with a ratio of 1:1.17. Their age is 32.5±13.6 years. The numbers and percentages of clinical staging were as following: 92 (13.7%) for stage 2 with TLC < 1200/ml, 430 (64.1%) for stage 3, 107 (15.9%) for stage 4 and 42 (6.3%) for CD4 count < 200/ml. Most of the cases, 604 (91%), remain minimal social function either in work or in school. None of the staff in Rainbow Clinic was found to have discrimination or stigmatization to patients. However, we still face some important challenges like over loading from the exceeding numbers of cases compared to a very limited staff.
Conclusions: Initial assessment and evaluation of this ARV scale-up plan at Rainbow clinic was considered successful. However, the increasing demand of the eligible cases and the drug sustainability could be a significant factor to the outcome in the future.